Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Sep;26(3):330–333. doi: 10.1111/j.1365-2125.1988.tb05285.x

Lack of effect of erythromycin on the pharmacokinetics of single oral doses of phenytoin.

R W Milne 1, K Coulthard 1, R L Nation 1, A C Penna 1, G Roberts 1, L N Sansom 1
PMCID: PMC1386547  PMID: 3179171

Abstract

The effect of erythromycin on the pharmacokinetics of phenytoin was studied in eight healthy volunteers using a balanced randomised cross-over design. Volunteers received a single oral dose of 400 mg of phenytoin sodium during each phase. During the treatment phase, the phenytoin sodium dose was administered 4.5 days after the commencement of a 7 day course of erythromycin base (250 mg every 6 h). There was no significant difference between the control and treatment phases (P greater than 0.05) with respect to the area under the plasma phenytoin concentration-time curve, the fraction of phenytoin unbound in plasma, the area under the unbound phenytoin concentration-time curve, the elimination half-life of phenytoin or the fraction of the dose excreted in urine as free and conjugated hydroxyphenylphenylhydantoin. This single dose study indicated that the intrinsic clearance of unbound phenytoin was unaffected by the concurrent administration of erythromycin.

Full text

PDF
330

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bachmann K., Schwartz J. I., Forney R. B., Jr, Jauregui L. Single dose phenytoin clearance during erythromycin treatment. Res Commun Chem Pathol Pharmacol. 1984 Nov;46(2):207–217. [PubMed] [Google Scholar]
  2. Glazko A. J., Peterson F. E., Chang T., Dill W. A., Smith T. C., Buchanan R. A. Phenytoin metabolism in subjects with long and short plasma half-lives. Ther Drug Monit. 1982;4(3):281–292. doi: 10.1097/00007691-198208000-00006. [DOI] [PubMed] [Google Scholar]
  3. Ludden T. M. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet. 1985 Jan-Feb;10(1):63–79. doi: 10.2165/00003088-198510010-00003. [DOI] [PubMed] [Google Scholar]
  4. Martin E., Tozer T. N., Sheiner L. B., Riegelman S. The clinical pharmacokinetics of phenytoin. J Pharmacokinet Biopharm. 1977 Dec;5(6):579–596. doi: 10.1007/BF01059685. [DOI] [PubMed] [Google Scholar]
  5. Perucca E. Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet. 1982 Jan-Feb;7(1):57–84. doi: 10.2165/00003088-198207010-00004. [DOI] [PubMed] [Google Scholar]
  6. Pessayre D. Effects of macrolide antibiotics on drug metabolism in rats and in humans. Int J Clin Pharmacol Res. 1983;3(6):449–458. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES